September 11, 2020

Santhera Announces Full Enrollment of ReveraGen’s VISION-DMD Study with Vamorolone in Duchenne

Santhera announced that ReveraGen’s VISION-DMD study for vamorolone in Duchenne has completed enrollment. Subject to a positive study outcome, this could allow for a regulatory submission to the FDA in the fourth quarter of 2021….

Learn More

September 2, 2020

Santhera Exercises Option to Obtain Worldwide Rights to Vamorolone in Duchenne and All Other Indications

We congratulate Santhera as they have exercised the option to obtain worldwide rights to vamorolone in Duchenne and all other indications. The license gives Santhera worldwide rights to vamorolone which means Santhera is responsible for…

Learn More

July 24, 2020

Catabasis Shares July 2020 Newsletter

Catabasis Pharmaceuticals has shared the latest edition of their community newsletter, which highlights the value of the North Star Ambulatory Assessment in Duchenne. Click here to download the PDF.

Learn More

June 2, 2020

Santhera Announces Completion of ReveraGen’s Long-Term Extension Study with Vamorolone in Duchenne

PPMD is excited to learn that Santhera Pharmaceuticals and partner ReveraGen Biopharma Inc. have completed a long-term, open-label extension study of 24 months duration with vamorolone in patients with Duchenne. Data from this study in…

Learn More

May 28, 2020

ReveraGen to Share Individual Patient Results with Trial Participants

ReveraGen has provided a letter to participants in their vamorolone trial indicating promising results with strength and mobility of patients on drug. Additionally, thanks to a NIH grant, ReveraGen will be sharing individual results with…

Learn More

May 20, 2020

Santhera Completes Enrollment of Phase 3 SIDEROS Study with Puldysa® (Idebenone) in Duchenne

Santhera announced today that their SIDEROS study is fully enrolled, with 254 participants ages 10-34 years old. PPMD is excited to learn that this trial is enrolled, allowing the study to continue and enabling Santhera…

Learn More

May 14, 2020

Catabasis Shares May 2020 Newsletter

Catabasis Pharmaceuticals has shared the latest edition of their community newsletter, including updates on edasalonexent and data shared during a recent scientific poster session. Click here to download the PDF.

Learn More

April 1, 2020

Santhera Shares Community Update on SIDEROS Trial & COVID-19

Santhera Pharmaceuticals has shared an update with the community regarding the SIDEROS clinical trial and their activities during the COVID-19 epidemic. Read the update from Santhera Dear Duchenne community, Much has changed in the world…

Learn More

March 26, 2020

Catabasis Shares March 2020 Newsletter

Catabasis Pharmaceuticals has shared the latest edition of their community newsletter, including information about edasalonexent and COVID-19, and responses to questions they have received. Click here to download the PDF.

Learn More

March 23, 2020

ReveraGen BioPharma Shares Community Update on Vamorolone Trials and COVID-19

ReveraGen has shared an update with the community regarding the Vamorolone trials and COVID-19. Read the Community Letter from ReveraGen Dear Duchenne families, As we are all confronted with the uncertainty of Covid-19, the team…

Learn More